Large Outflow of Money Witnessed in Pacira Pharmaceuticals

Pacira Pharmaceuticals (PCRX) : The value of composite uptick trades was $3.5 million, whereas, the value of composite downtick trades was $7.11 million. The uptick to downtick ratio stood at 0.49 with a negative money flow of ($3.6) Million during Wednesdays trading session. The block trades money flow was negative ($3.67 million). The transaction of the trades on downticks amounted to $3.67 million, which confirms investors selling on the strength of price. Pacira Pharmaceuticals (PCRX) gained 5 cents at $35.51, an increase of 0.14% over the previous days close.


Pacira Pharmaceuticals, Inc. has lost 3.42% in the last five trading days and dropped 9.98% in the last 4 weeks. Pacira Pharmaceuticals, Inc. has dropped 6.47% during the last 3-month period . Year-to-Date the stock performance stands at -53.7%.

Pacira Pharmaceuticals (PCRX) : 9 analysts are covering Pacira Pharmaceuticals (PCRX) and their average rating on the stock is 1.67, which is read as a Buy. 6 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 1, which recommends a Strong Buy affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened at $35.67 and touched an intraday high of $36.03 on Wednesday. During the day, the stock corrected to an intraday low of $34.83, however, the bulls stepped in and pushed the price higher to close in the green at $35.55 with a gain of 0.25% for the day. The total traded volume for the day was 677,393. The stock had closed at $35.46 in the previous trading session.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *